Trademark: KALVISTA 2303886
Word
KALVISTA
ID
2303886
Trademark Type
Word
Status
Protected: Registered/protected
Application Date
20 July 2022
Registration Date
20 July 2022
Renewal Date
20 July 2032
Owner(s)
Service
Davies Collison Cave Pty Ltd
Goods and Services:
Class 5:
Pharmaceutical preparations for the treatment of ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of diabetic macular edema; pharmaceutical preparations for the treatment of angioedema; pharmaceutical preparations for the treatment of hereditary angioedema; pharmaceutical preparations for the treatment of diseases and disorders mediated by the contact activation system; pharmaceutical preparations for the treatment of plasma kallikrein or factor XIIa mediated diseases or disorders.
Pharmaceutical preparations for the treatment of ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of diabetic macular edema; pharmaceutical preparations for the treatment of angioedema; pharmaceutical preparations for the treatment of hereditary angioedema; pharmaceutical preparations for the treatment of diseases and disorders mediated by the contact activation system; pharmaceutical preparations for the treatment of plasma kallikrein or factor XIIa mediated diseases or disorders.
Class 10:
Medical and surgical instruments and apparatus for use in the treatment of ophthalmic diseases and disorders, diabetic macular edema, angioedema, hereditary angioedema, diseases and disorders mediated by the contact activation system, and plasma kallikrein or factor XIIa mediated diseases or disorders; drug delivery devices for use in the treatment of ophthalmic diseases and disorders, diabetic macular edema, angioedema, hereditary angioedema, diseases and disorders mediated by the contact activation system, and plasma kallikrein or factor XIIa mediated diseases or disorders.
Medical and surgical instruments and apparatus for use in the treatment of ophthalmic diseases and disorders, diabetic macular edema, angioedema, hereditary angioedema, diseases and disorders mediated by the contact activation system, and plasma kallikrein or factor XIIa mediated diseases or disorders; drug delivery devices for use in the treatment of ophthalmic diseases and disorders, diabetic macular edema, angioedema, hereditary angioedema, diseases and disorders mediated by the contact activation system, and plasma kallikrein or factor XIIa mediated diseases or disorders.
Class 42:
Drug discovery services relating to ophthalmic diseases and disorders; drug discovery services relating to diabetic macular edema; drug discovery services relating to angioedema; drug discovery services relating to hereditary angioedema; drug discovery services relating to diseases and disorders mediated by the contact activation system; drug discovery services relating to plasma kallikrein or factor XIIa mediated diseases or disorders.
Drug discovery services relating to ophthalmic diseases and disorders; drug discovery services relating to diabetic macular edema; drug discovery services relating to angioedema; drug discovery services relating to hereditary angioedema; drug discovery services relating to diseases and disorders mediated by the contact activation system; drug discovery services relating to plasma kallikrein or factor XIIa mediated diseases or disorders.
Class 44:
Medical and healthcare services relating to ophthalmic diseases and disorders; medical and health care services relating to diabetic macular edema; medical and healthcare services relating to angioedema; medical and healthcare services relating to hereditary angioedema; medical and healthcare services relating to diseases and disorders mediated by the contact activation system; medical and healthcare services relating to plasma kallikrein or factor XIIa mediated diseases or disorders.
Medical and healthcare services relating to ophthalmic diseases and disorders; medical and health care services relating to diabetic macular edema; medical and healthcare services relating to angioedema; medical and healthcare services relating to hereditary angioedema; medical and healthcare services relating to diseases and disorders mediated by the contact activation system; medical and healthcare services relating to plasma kallikrein or factor XIIa mediated diseases or disorders.